https://lifescienceleader.com

Life Science Leader - Home PageLife Science Leader - thought leadership articles and discussions about the current life science industryLife Science Leader - Home Page Get more Life Science Leader insight with our FREE newsletter. sign me up Log In or Subscribe Home Magazine Past Issues Digital Edition Articles Executive Interviews Companies To Watch Where Are They Now Industry Leader CEO Corner Ask The Board Key Topics Clinical Trials Finance-Funding Outsourcing Regulatory Research & Development Improving The Clinical Trial Ecosystem: A Call To Stakeholder Alignment Biopharmaceutical companies must address the frictions and challenges that have quietly infiltrated the drug development ecosystem and root them out, planting instead a new spirit of partnership and collaboration. 'Explainambiguity:' When What You Think Is Not What You Get A Systems Approach To Parkinson's Disease Companies To Watch: Aurion Biotech Google Life Sciences Leader Talks AI Opportunities And 'Watch Outs' For Biopharma 'Doers, not Leaders': How Women Can Overcome A Common Workplace Struggle This Takeda Official Thinks Pharma 4.0 Won't Be Optional Much Longer Mid-Year M&A Outlook: Challenges And Opportunities Update Where Are They Now? Caribou Biosciences GLP-1 Drugs Driving Big Budget Impact: PwC's Medical Cost Trend 2025 An Updated View Of The Federal Segment: Veterans Affairs Formulary Management More Articles COMPANIES TO WATCH Companies To Watch: Aurion Biotech Aurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases. Companies To Watch: Athira Pharma Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease. Companies To Watch: Volastra Therapeutics Volastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow. Companies To Watch: OSE Immunotherapeutics OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need. More Companies To Watch WHERE ARE THEY NOW Where Are They Now? Caribou Biosciences Caribou Biosciences is gunning for a Phase 3 pivotal trial start in 2025 for lead candidate CB-010, after cutting its CAR-NK preclinical activities to focus exclusively on developing CB-010 and two additional allogeneic CAR-T therapies. Where Are They Now? Otsuka Otsuka Precision Health, a new subsidiary focused on digital therapeutics and other tech-enabled solutions for patients, is a continuation of the company's broader mission described by an Otsuka executive in the pages of Life Science Leader eight years ago. Where Are They Now? SQZ Biotech SQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices. More Where Are They Now NEWSLETTER ARCHIVE 09.11.24 -- 'Watch Outs' For Biopharma And AI Opportunities With Shweta Maniar 09.10.24 -- All Eyes On Sustainability 09.09.24 -- The Role Of Physician Intelligence In Drug Discovery And Development 09.09.24 -- Accelerate Development Timelines With A Robust CLD Strategy 09.06.24 -- How DEI Sets A High Bar For Leadership More Newsletters Newsletter Signup Get the latest articles from Life Science Leader delivered to your inbox. I agree to the Terms. I agree to the Privacy Statement. SIGN ME UP A Systems Approach To Parkinson's Disease GLP-1 Drugs Driving Big Budget Impact: PwC's Medical Cost Trend 2025 Reading The Room In Oncology Drug Development Ten Years In, Project Data Sphere Is Snowballing Drug Discovery And Development, Powered By Physician Intelligence More From The Editor SPOTLIGHT Cash Needed For Phase 3 Celiac Drug Development Industry veteran James Sapirstein, CEO of Entero Therapeutics, discusses the company's lead candidate, a treatment for celiac disease, and makes the case for investors and Big Pharma to step up and help bring it across the finish line. More Spotlight Articles LIFE SCIENCE LEADER CONTENT COLLECTIONS Adapting With Automation: A Guide For The Modern Lab Vaccine Maker's Toolkit: Strategies For Manufacturing And Supply Management Scaling Cell and Gene Therapies Your Supply Chain On Inflation: An Outsourcing Analysis Improving Diversity In Clinical Trials More Content Collections This website uses cookies to ensure you get the best experience on our website. Learn more Got it! Partner With Us Our Partners Request More Information Subscribe Newsletter Subscription Life Science Connect Advancing RNA Bioprocess Online Biosimilar Development Cell & Gene Clinical Leader Clinical Supply Leader Clinical Tech Leader Drug Discovery Drug Delivery Leader Laboratory Network Med Device Online Outsourced Pharma Pharmaceutical Online Editorial Current Issue Past Issues Digital Edition Article Reprints Editorial Advisory Board Editorial Submission Guidelines Events CMO Leadership Awards CRO Leadership Awards Learn More About Us Contact Us Who We Are Work For Us Copyright © 1996-2024 VertMarkets, Inc. All Rights Reserved. Terms of Use. Privacy Statement. Subscriber Request Form. Don't sell my information ×https://lifescienceleader.com

Sahypaňyzy redaktirläňmi?

Näme edýärsiň?